41 results about "Hemorrhagic risk" patented technology

Platelet contractile force and/or clot elastic modulus measurements are used to identify patients at risk for atherosclerosis or for bleeding during surgical procedures or other applications. Measurements which are elevated are indicative of atherosclerosis, and measurements which are reduced are indicative of a bleeding risk.

Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that retain normal levels of anti-apoptotic activity are provided. Two examples of such recombinant APC mutants are KKK191-193AAA-APC and RR229/230M-APC. APC variants and prodrugs of the invention have the desirable property of being cytoprotective (anti-apoptotic effects), while having significantly reduced risk of bleeding. The invention also provides a method of using the APC variants or prodrugs of the invention to treat subjects who will benefit from APC's cytoprotective activities that are independent of APC's anticoagulant activity. These subjects include patients at risk of damage to blood vessels or tissue in various organs caused, at least in part, by apoptosis. At risk patients include, for example, those suffering (severe) sepsis, ischemia/reperfusion injury, ischemic stroke, acute myocardial infarction, acute or chronic neurodegenerative diseases, or those undergoing organ transplantation or chemotherapy, among other conditions. Methods of screening for variants of recombinant protein C or APC that are useful in accordance with the invention are also provided.

Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that retain normal levels of anti-apoptotic activity are provided. Three examples of such recombinant APC mutants are KKK191-193AAA-APC, RR229/230AA-APC, and RR229/230AA plus KKK191-193AAA-APC. APC variants and prodrugs of the invention have the desirable property of being cytoprotective (anti-apoptotic effects), while having significantly reduced risk of bleeding. The invention also provides a method of using the APC variants or prodrugs of the invention to treat subjects who will benefit from APC's cytoprotective activities that are independent of APC's anticoagulant activity. These subjects include patients at risk of damage to blood vessels or tissue in various organs caused, at least in part, by apoptosis. At risk patients include, for example, those suffering (severe) sepsis, ischemia/reperfusion injury, ischemic stroke, acute myocardial infarction, acute or chronic neurodegenerative diseases, or those undergoing organ transplantation or chemotherapy, among other conditions. Methods of screening for variants of recombinant protein C or APC that are useful in accordance with the invention are also provided.

The invention provides a prasugrel eutectic with a structure shown in the specification, and a preparation method, a medicinal composition and application thereof. The prasugrel eutectic does not contain a solvent and is low in hygroscopicity, so that the preparation and storage of Chinese herbal medicines are facilitated. Experiments for testing dissolubility prove that the prasugrel eutectic is relatively low in dissolution speed, so the prasugrel eutectic can be used as a sustained-release agent for prasugrel medicines to overcome the defect of increasing hemorrhagic risks. In addition, the method for preparing the prasugrel eutectic is simple, and easy to operate.

Platelet contractile force (PCF) is used as a surrogate marker of thrombin generation. PCF generation occurs concomitant with the burst of prothrombin fragment F 1+2 release. The time between assay start and PCF onset is identified as the thrombin generation time (TGT), and is used in assessing risk of bleeding, in diagnosing various disorders, and in monitoring the effects of pharmaceutical and other treatments. TGT is prolonged in clotting factor deficiencies and in the presence of direct and indirect thrombin inhibitors. TGT shortens to normal with clotting factor replacement and shortens with administration of rVIIa. TGT is short in thrombophilic states such as coronary artery disease, diabetes and thromboangiitis obliterans and prolongs toward normal with oral and intravenous anticoagulants.

The invention relates to an in-vitro method for diagnosing Von Willebrand Disease (VWD) and an increased bleeding risk associated with Von Willebrand Disease and/or acquired or congenital platelet function defects that reduce the interactions of Von Willebrand Factor (VWF) with platelets. The in-vitro method of the invention may also be used to diagnose further bleeding risks. The test is suitable for use as a screening test based on whole blood and has the additional benefit of being suitable as a point of care test. The method involves the incubation of a sample containing platelets and hemostasis factors with an activator of platelet aggregation and the measurement of the viscoelastic change after inducing coagulation, e.g., by means of thromboelastography (TEG).

The invention discloses a blood vessel prosthesis stent for Stanford type A aortic dissection. The blood vessel prosthesis stent comprises a main stent body, wherein a single branch or two branches is or are fixed at a proximal end of the main stent body. With the adoption of the blood vessel prosthesis stent, the amount of vascular anastomosis of a patient with Stanford type A aortic dissection affecting the aortic arch part can be effectively reduced, the surgical procedures are simplified, the risk of hemorrhage is reduced, deep hypothermic circulatory arrest and low-flow cerebral protection time in the period of cardiovascular arrest are shortened, so that the surgical treatment effect of the patient with the Stanford type A aortic dissection is improved, and the blood vessel prosthesis stent can be popularized in primary hospitals.

The invention relates to the field of lauromacrogol injection drug application, and discloses application of lauromacrogol injection as a drug for curing cesarean scar pregnancy. The drug is applied according to the following steps: step (1), a focus scope, a muscular layer thickness and the blood supply situation of a focus location are determined by ultrasound contrast; step (2), the vagina is conventionally disinfected and a towel is spread at a lithotomy position of a patient; step (3), under ultrasonic guidance, the lauromacrogol injection is injected at a peripheral muscular layer of a gestational sac and around the gestational sac, until annular or flaky reinforcement of the gestational sac is seen under ultrasound and peripheral blood is sparse, wherein the specification of the lauromacrogol injection is that each 10ml of injection contains 100mg of lauromacrogol. According to the application of the lauromacrogol injection as the drug for curing cesarean scar pregnancy, the lauromacrogol injection is adhered to the inside of a vessel at the injection site, thus prompting a fibrosis strip to replace the pathological vessel, resulting in permanent occlusion of the vessel around the gestational sac, interdicting an open vessel at the pathological location, and greatly reducing bleeding risk in induced abortion operation.

The invention belongs to the technical field of medicine and particularly relates to a method and system for evaluating the bleeding risk of esophagus and stomach fundus varicosity of a cirrhosis patient. It is discovered through research that the SAAG and varix degree of the esophagus and stomach fundus of the patient with cirrhosis ascites have obvious relevance, and the higher the level of therelevance is, the more serious the stomach fundus varicosity of the esophagus is; when SAAG is larger than or equal to 25 g/L, the bleeding risk of esophagus and stomach fundus phleborrhexis of the patient within one year is obviously increased. By means of the method and system, the value of predicting bleeding of varicosity and phleborrhexis of the esophagus and stomach fundus within one year bythe system can be evaluated.

The invention discloses a tetrahydrothienopyridine deuterated derivative as well as a preparation method and pharmaceutical application thereof. The derivative can be used for preparing medicines for preventing or treating thrombus-related diseases. The thienopyridine derivative can balance and optimize the safety and effectiveness of a medicine, the thienopyridine derivative is prevented from being hydrolyzed too fast in the gastrointestinal tract, and a better treatment effect is achieved on the premise that the bleeding risk of a patient is not increased.

The invention discloses a method for establishing a bleeding risk predicting model of an acute coronary syndrome after an interventional therapy, wherein the method belongs to the field of risk predicting. The method comprises the following steps of S1, collecting data from a hospital electronic medical record system; S2, screening the acute coronary syndrome patient of percutaneous coronary intervention, and extracting the required patient information; S3, applying a machine learning method for establishing patient postoperative short-and-long-term bleeding risk predicting models; and S4, evaluating the prediction value of each model, and selecting an optimal predicting model. Through retrospectively collecting the information of the acute coronary syndrome patient in the hospital electronic medical record system, collection is completely performed on the information of the acute coronary syndrome patient. Furthermore through multiple models in which machine learning is applied, the model which uses the patient information for predicting the bleeding risk is established, thereby realizing certain meaning in guiding clinical treatment decision and reducing bleeding incidence rate.

The invention discloses a method for preparing an efficient blood coagulation resistant biomaterial with an aqueous solution. The aqueous solution has a self-assembly characteristic, is high in biochemistry activity, can form hydrogen bonds with anticoagulation/antithrombus medicines, and has the characteristic of being firmly attached to the biomaterial, so that the surface of the biomaterial (such as a blood purification film, a blood purification pipeline, a cardiovascular stent and an artificial blood vessel) has anticoagulation/antithrombus activity. The surface modification process disclosed by the invention is simple in experimental condition, high in controllability, economical and environment-friendly; and the aqueous solution is high in shaping properties, so that the aqueous solution is basically suitable for anticoagulation/antithrombus modification of the surface of the biomaterial in any shape. The dopamine hydrochloride aqueous solution is prepared, a micromolecule anticoagulant medicine-argatroban is grafted to the surface of a haemodialysis film, the haemodialysis film having anticoagulation/antithrombus activity is successfully prepared, the usage of a whole bodyanticoagulant is reduced or avoided, and the bleeding risk of a haemodialysis patient is reduced.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of FXI RNA in a cell or subject, and in certain instances reducing the amount of FXI protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to prevent, treat, or ameliorate at least one symptom of a thromboembolic condition without a significant increase in a bleeding risk. Such thromboembolic conditions include deep vein thrombosis, venous or arterial thrombosis, pulmonary embolism, myocardial infarction, stroke, thrombosis associated with chronic kidney disease or end-stage renal disease (ESRD), including thrombosis associated with dialysis, or other procoagulant condition. Such symptoms include decreased blood flow through an affected vessel, death of tissue, and death.

Recombinant activated protein C (APC) and APC variants with reduced anticoagulant activity were used to reduce mortality in murine models of sepsis. These models included endotoxemia and bacteremia models. We discovered that single or multiple bolus doses of APC, especially of APC variants such as RR230/231AA-APC, KKK192-194AAA-APC and 5A-APC (containing the combination of mutations present in the first two APC variants) given as a single bolus reduces 7-day mortality of mice given lethal doses of endotoxin. Administrations of a single bolus of 5A-APC after the initiation of sepsis also reduces mortality caused by LPS. 5A-APC with ≦8% of normal anticoagulant activity (which has reduced risk of bleeding) reduces mortality when given as two bolus administrations at 3 hours and then at 10 hours after initiation of bacterial infection, i.e. after onset of sepsis. This shows, first, that one or more bolus injections of APC or of APC variants, especially 5A-APC, can reduce mortality when given beginning hours after the onset of sepsis and, second, that it is not necessary to administer APC as a continuous infusion which is the current standard of practice because one or more bolus administrations can reduce mortality. Furthermore, dosages of approximately 0.06 to 0.4 mg/kg of APC and APC variants are identified to be sufficient to reduce mortality in sepsis.

The invention relates to a hemostasis device, in particular to a hemostasis device for a hepatobiliary surgery. The situation that external force pulls an operative incision can be effectively prevented, automatical nursing and changing of medicines can be carried out, and the problem of reducing the physical burden of medical personnel when a compression hemostasis method is adopted during bleeding of the operative incision is solved. An arranged locking bleeding-preventing device can effectively prevent bleeding caused by pulling of the operative incision due to lateral movement of skin around a wound, an arranged dressing change device and a gauze fixing device can conveniently and rapidly nurse the operation incision, the operation incision can be healed benign and rapidly, and the bleeding risk is reduced. An arranged compression hemostasis device can be used for mechanically compressing the operation incision, medical workers do not need to pay too much physical strength, the medical workers have more energy to cope with other conditions, and the device can prevent bleeding and can further effectively cope with the bleeding condition.

The invention relates to a novel bellyband used after a kidney puncture operation. The novel bellyband comprises a left wing part, a middle section part, a right wing part and an overlapping part which are connected in sequence; the outer end part of the left wing part is provided with a bonding part corresponding to the overlapping part; the middle parts of the left wing part and the right wing part are respectively provided with an inflating bag which is used for pressing and is provided with an inflating catheter; and a traditional Chinese medicine patch is arranged in the middle of the middle section part, and a small air bag with an inflation catheter is arranged below the traditional Chinese medicine patch and used for stimulating acupuncture points. A doctor only needs to inflate and deflate to achieve the purposes of compression, recompression and compression relief according to the illness condition, and the risk of hemorrhage after renal puncture caused by changing the body position of a patient or improperly exerting force is reduced; and the traditional Chinese medicine is combined, acupoint stimulation and traditional Chinese medicine external application are utilized, urination is promoted, anxiety and discomfort caused by dysuria are reduced, and catheterization is avoided.

The invention relates to a method for identification of an individual at increased risk of thrombosis or an atherothrombotic event, or a major bleeding event, comprising a step of assaying a biological sample from the individual for the presence of a SNP in the PPARGC1β, CNTN4, LZTS1 and KCNE4 genes, wherein the presence of a SNP in the PPARGC1β, CNTN4, LZTS1 and KCNE4 genes correlates with the individual being at increased risk of thrombosis or an atherothrombotic event, or a major bleeding event. Typically, the SNP is selected from the SNPs provided in Tables 1 and 2. The invention also provides a method of identifying an individual most likely to gain benefit from single anti-platelet therapy in the primary prevention of cardiovascular events, a method of identifying an individual most likely to gain benefit from dual anti-platelet therapy in the secondary prevention of cardiovascular events, and a method of identifying an individual likely to suffer a significant bleeding complication when undergoing treatment with drugs which influence haemostasis.

The invention relates to a method of determining the bleeding risk of a subject comprising:

• • a. contacting a first sample from the subject with an activation mixture comprising (I) TIX-5, (II) factor Xa or an activation agent for activating directly or indirectly the conversion of factor X to factor Xa, and (III) a phospholipid mixture,
  • b. determining the value of a coagulation function parameter of said sample,
  • c. comparing the coagulation function parameter with a control value,
  • d. determining the bleeding risk based on a comparison between the value of said coagulation function parameter of said first sample and said control value.